ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2023

A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout

Frank Fan1, Riyong Liu1 and Yu Wang2, 1Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), 2Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)

Meeting: ACR Convergence 2024

Keywords: clinical trial, gout, hyperuricemia, Randomized Trial, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of oral urate-lowering therapies, pegloticase is often prescribed. In many such patients, pegloticase, a porcine-like uricase conjugated to 10-kDa methoxy-poly(ethylene glycol) (PEG), is very effective, especially when co-administered with methoxtrexate, but it is expensive, involves biweekly intravenous infusions, and may trigger serious allergic reactions. In efforts to mitigate those disadvantages, we have developed a different PEG-uricase, called PU5 (or PJ003), which is stable in vivo, has favorable pharmacodynamics (PD) and low immunogenicity and can be injected intramuscularly (IM).

Methods: A porcine-like uricase was synthesized by recombinant expression in Escherichia coli. It was PEGylated by reaction with an N-hydroxysuccinimide propionate derivative of 5-kDa PEG at a high pH. The resulting conjugates were purified chromatographically. The protein concentration was measured by the Lowry method and uricolytic activity was measured using UV absorbance. An average of 11 lysine side-chains were modified per subunit of uricase, assessed using SEC-HPLC, with detection by a combination of UV absorbance and refractive index. The primary sites of modification were identified by peptide mapping, following cleavage of uricase and PU5 by Lys-C and/or Trypsin. Pre-clinical studies of PU5 were performed using chronic hyperuricemia models in Sprague-Dawley (SD) rats and Beagle dogs. The Phase I clinical trial was a single-center, randomized, double-blind, placebo-controlled, single dose, and dose escalation trial. Healthy subjects were enrolled and the tolerability, pharmacokinetics (PK), PD and immunogenicity were assessed after one IM injection.

Results: (1) Figure 1 shows the key PD results obtained after an IM injection of PU5 in SD rats:

(2)Figure 2 shows the key results from the Phase I clinical trial; Intramuscular administration of the following doses: 0.96, 3, 6, 9, and 12 mg, resulted in good safety and low immunogenicity. There were 25 male and 5 female trial subjects with a mean body weight of 67 kg (range of 54 to 88 kg) and a mean age of 31 years (range of 22 to 45 years). The magnitude of the decrease in plasma uric acid (PUA) increased with the dose of PU5 and the duration of decreased PUA was positively correlated with the dose. Following a single dose of PU5 (6 – 12 mg), the PUA remained below 200 µmol/L for at least 336 hours. The time to maximal reduction of PUA (Tmax) was about 120-180 hours.

Conclusion: The Phase I clinical trial data indicated that PU5 is safe in healthy humans and has promising PK/PD and immunologic characteristics. More detailed information about PU5, including its amino acid sequence, preparation and characterization, pre-clinical PK/PD data, and Phase I clinical data, will be presented at the meeting.

Supporting image 1

Changes in plasma uric acid (PUA) levels after a low, medium or high dose of PU5 (0.3, 1.0 or 3.0 mg uricase protein/kg).

Supporting image 2

Changes in plasma uric acid levels of healthy Han Chinese.


Disclosures: F. Fan: None; R. Liu: None; Y. Wang: None.

To cite this abstract in AMA style:

Fan F, Liu R, Wang Y. A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-pegylated-mammalian-uricase-suitable-for-intramuscular-administration-to-patients-with-refractory-chronic-gout/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-pegylated-mammalian-uricase-suitable-for-intramuscular-administration-to-patients-with-refractory-chronic-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology